OptiBiotix Health has issued 800,000 shares priced at £0.08 ($0.11) a share in a private placement to raise £0.064m ($0.089m).

OptiBiotix is a UK-based life sciences company.

US-based biopharmaceutical company CTI BioPharma has issued an underwritten public offering of shares of its common stock. The company will grant underwriters a 30-day option to buy additional shares.

The proceeds are intended to be used towards the completion of the PAC203 clinical trial and for general corporate purposes, including research and development, and pre-clinical and clinical trials.

“US-based biopharmaceutical company NovaBay Pharmaceuticals has issued 1.7 million shares priced at $3.52 a share in a private placement to raise $5.98m.”

CTI BioPharma has appointed Leerink Partners as the sole book-running manager and JMP Securities as the senior lead manager for the transaction.

Needham & Company and Oppenheimer & Co have been appointed as lead managers, and O’Melveny & Myers as the legal advisor.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

US-based biopharmaceutical company NovaBay Pharmaceuticals has issued 1.7 million shares priced at $3.52 a share in a private placement to raise $5.98m.

OP Financial Investments has subscribed to the placement.

NovaBay Pharmaceuticals has appointed China Kington Asset Management as the placement agent for the transaction.